A cross-party group of MPs has issued a critique of the government’s current strategy for distributing Mounjaro, a medication recently approved for weight management. The lawmakers described the existing rollout plans as "unambitious," arguing that the current framework will only provide access to a "woefully small number of people" who could benefit from the treatment.

The MPs are calling for an urgent boost to the rollout, suggesting that the current pace and scale of the program do not align with the clinical need for obesity interventions. While the drug has been cleared for use within the National Health Service, the implementation strategy has become a point of contention among those who believe the government is moving too slowly to address the public health crisis. The critique highlights a disconnect between the medical approval of the drug and the practical logistics of making it widely available to patients across the country. As of now, the government has not provided a detailed response to the specific criticisms regarding the scale of the rollout, leaving the future pace of the program uncertain.